EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Glutamate biomarkers in comprehensive diagnostics of acute and chronic brain ischemia

Grigory V. Ponomarev, Igor A. Vozniuk, Marina A. Izumi, Alexander A. Skoromets

Annals of Clinical and Experimental Neurology · 29.12.2020 · 14 (4)

DOI: 10.25692/acen.2020.4.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, erschienen am 29.12.2020. Verfasst von Grigory V. Ponomarev und 3 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development and implementation of biomarkers of ischaemic brain damage at the pre-hospital and hospital stages, as well as during screening and regular medical examinations, are a priority in neurology. This review describes the role of NR2 peptide, a subunit of the NMDA ionotropic glutamate receptors, in the pathogenesis of cerebral ischemia. Experimental data are presented, showing that NR2 peptide expression increases in brain ischemia, its fragments passing through the blood-brain barrier and entering the bloodstream, thus stimulating the immune response and autoantibody production. Key studies are reviewed that have demonstrated the possibility of using glutamate receptors and their antibodies as potential biomarkers of acute and chronic cerebral ischemia. The sensitivity and specificity of NR2 peptide and NR2 antibodies in these studies averaged >90%. It has been shown that NR2A/B is the only marker with high negative and positive predictive value in people with suspected ischaemic stroke. Monitoring treatment effectiveness is another promising area of application for glutamate biomarkers. Previous studies have shown that the NR2 peptide and its antibodies are potential biomarkers of cerebral infarction, transient ischaemic attack, and chronic cerebral ischemia and may become important components in a successful and comprehensive approach to treatment, screening, and monitoring of disease outcomes.

Zitieren

APA

Ponomarev, G. V., Vozniuk, I. A., Izumi, M. A., & Skoromets, A. A. (2020). Glutamate biomarkers in comprehensive diagnostics of acute and chronic brain ischemia. Annals of Clinical and Experimental Neurology, 14(4). https://doi.org/10.25692/acen.2020.4.2

Vancouver

Ponomarev GV, Vozniuk IA, Izumi MA, Skoromets AA. Glutamate biomarkers in comprehensive diagnostics of acute and chronic brain ischemia. Annals of Clinical and Experimental Neurology. 2020;14(4). doi:10.25692/acen.2020.4.2

BibTeX
@article{Ponomarev2020,
  author = {Ponomarev, Grigory V. and Vozniuk, Igor A. and Izumi, Marina A. and Skoromets, Alexander A.},
  title = {Glutamate biomarkers in comprehensive diagnostics of acute and chronic brain ischemia},
  journal = {Annals of Clinical and Experimental Neurology},
  year = {2020},
  volume = {14},
  number = {4},
  doi = {10.25692/acen.2020.4.2}
}
Kostenlos starten →